With auranofin being an FDA-approved anti-inflammatory gold compound inhibiting TrxR1 [25,27,28] and currently being evaluated in clinical trials for repurposing in cancer treatment (see https://www.clinicaltrials.gov), and with TXNL1 yet having poorly understood functions, we here wished to further characterize the biochemical properties of TXNL1. This evidence concerns the gene TXNL1 and cancer.